Drug Discovery Today

OCTOBER 6, 2020

Validated research tool to be used to predict disease severity and individual therapeutic response to COVID-19 in aid of rapid vaccine and drug development

Disease 113

Disease Government Research Vaccine 113

The Pharma Data

JULY 23, 2021

government has purchased an additional 200 million doses of the Pfizer-BioNTech COVID-19 Vaccine. government under its existing supply agreement to 500 million. government with 500 million doses of the companies’ COVID-19 vaccine for donation to the world’s poorest nations. This press release features multimedia.

Vaccine 52

Vaccine Government Immune Response FDA 52

Drug Discovery World

MAY 15, 2024

Initial funding will support solutions to address the health impacts of climate change; infectious disease and antimicrobial resistance (AMR); and greater understanding of the interplay between nutrition, immunity, disease, and developmental outcomes. “By

Science 147

Science Disease Government Vaccine 147

The Pharma Data

OCTOBER 28, 2021

GOVERNMENT AN Fresh 50 MILLION PEDIATRIC Boluses OF COVID-19 VACCINE TO SUPPORT Farther PREPAREDNESS FOR FUTURE NEEDS. government has bought 50 million further boluses of the companies’COVID-19 vaccine. government has exercised its final purchase option under its beingU.S. PFIZER AND BIONTECH TO GiveU.S.

Government 52

Government Vaccine Clinical Trials FDA 52

Drug Discovery World

JUNE 9, 2023

The University of Queensland (UQ), Australia, and Emory University in Atlanta, US, have committed to scaling up their collaboration to focus on pandemic preparedness and regional disease prevention. This is a crucial step in getting new vaccine candidates from the lab to the community in the shortest possible time,” Professor Terry added.

Vaccine 130

Vaccine Clinical Trials Virus Government 130

The Pharma Data

APRIL 26, 2022

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. NYSE: PFE) today reported positive Phase 2 pediatric data for their Lyme disease vaccine candidate, VLA15.

Vaccine 52

Vaccine Disease Protein Expression Trials 52

The Pharma Data

AUGUST 5, 2020

Government for 100 Million Doses of Investigational COVID-19 Vaccine. Government for 100 Million Doses of Investigational COVID-19 Vaccine. Company working to ensure broad global access to COVID-19 vaccine candidate, following approval from regulators. Johnson & Johnson Announces Agreement with U.S.

Government 52

Government Vaccine Pharmaceutical Companies Regulations 52

The Pharma Data

JULY 21, 2021

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, and Pfizer Inc. at Month 7). Juan Carlos Jaramillo M.D., About VLA15.

Vaccine 52

Vaccine Disease Trials Protein Expression 52

Drug Discovery World

JANUARY 21, 2024

Inspired by the overall event theme of ‘Innovation at Every Turn’, the DDW track will present leading research and case studies from experts in academia, government agencies and the industry on how technology is innovating from bench to bedside, lab to patient. It is sponsored by Integra Biosciences and Hamamatsu Corporation.

Vaccine 130

Vaccine Computational Chemistry Animal Testing Engineering 130

The Pharma Data

DECEMBER 16, 2020

(Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced an Advance Purchase Agreement with the government of New Zealand for the purchase of 10.7 million doses of NVX-CoV2373, Novavax’ candidate vaccine against COVID-19. About NVX-CoV2373.

Government 52

Government Vaccine Immune Response Clinical Trials 52

The Pharma Data

OCTOBER 28, 2020

OSAKA, Japan–( BUSINESS WIRE )– Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK), announced today that it will import and distribute 50 million doses of Moderna’s COVID-19 vaccine candidate, mRNA-1273, starting in the first half of 2021, pending licensure in Japan. President of the Global Vaccine Business Unit, Takeda.

Government 40

Government Vaccine Pharmaceutical Companies Pharmaceuticals 40

The Pharma Data

AUGUST 5, 2020

Company working to ensure broad global access to COVID-19 vaccine candidate, following approval from regulators. government for the large scale domestic manufacturing and delivery in the U.S. of 100 million doses of Janssen’s SARS-CoV-2 investigational vaccine, Ad26.COV2.S, NEW BRUNSWICK, N.J., NEW BRUNSWICK, N.J.,

Government 40

Government Vaccine Pharmaceutical Companies Regulations 40

The Pharma Data

SEPTEMBER 25, 2020

A trial of a new vaccine that appears to train the immune system to fight coronavirus has begun in the UK. The trial on 10,000 people will now see if the vaccine can prevent people getting ill. The UK government has already ordered 60 million doses in case it proves successful. Image copyright. Image caption.

Vaccine 52

Vaccine Trials Immune Response Virus 52

Drug Discovery World

DECEMBER 13, 2023

The event will take place on 5 and 6 February 2024 at SLAS in Boston, and will present leading research from experts in academia, government agencies and industry on how technology is innovating from bench to bedside, lab to patient. Register now to show your interest.

Engineering 130

Engineering Government Vaccine Science 130

The Pharma Data

AUGUST 14, 2020

Parents are being urged to make sure their children are up-to-date with all their routine vaccinations. The Local Government Association said high vaccine uptake could prevent infections and stop pressure being piled on the NHS. Vaccines protect children against serious diseases including measles, meningitis and whooping cough.

Vaccine 52

Vaccine Government Disease Research 52

The Pharma Data

MAY 22, 2023

WHO launches global network to detect and prevent infectious disease threats WHO and partners are launching a global network to help protect people from infectious disease threats through the power of pathogen genomics. Diseases do not respect borders: a disease threat in one country is also a threat to others.

Disease 52

Disease Bioinformatics Virus Vaccine 52

The Pharma Data

DECEMBER 17, 2020

Advisory Committee Votes to Recommend EUA for Moderna Vaccine. 17, 2020 — The Moderna COVID-19 vaccine received recommendation from a U.S. Food and Drug Administration advisory committee on Thursday, clearing the way for it to become the second COVID-19 vaccine to be granted emergency use authorization. THURSDAY, Dec.

Vaccine 52

Vaccine Government Clinical Trials FDA 52

Drug Discovery World

JANUARY 31, 2024

The line-up of speakers is a reminder of how much insight there is in our community across academia, government agencies and industry – and the value of connecting these. At events such as SLAS2024, we are all reminded of how important it is to meet, network and innovate in order to facilitate growth.

Government 130

Government Vaccine Disease Science 130

Drug Discovery World

AUGUST 31, 2022

Biotechnology company Moderna has filed a patent infringement lawsuit against Pfizer and BioNTech in relation to the use of its messenger RNA (mRNA) technology and Pfizer and BioNTech’s Covid-19 Comirnaty vaccine. Moderna alleges that Pfizer and BioNTech copied this technology, without Moderna’s permission, to make Comirnaty.

Vaccine 130

Vaccine RNA Licensing Licensing 130

The Pharma Data

FEBRUARY 24, 2022

A vaccine manufactured in plants and developed in Canada. Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) today announced that Health Canada has granted approval for COVIFENZ®, COVID-19 vaccine, (plant-based virus-like particles [VLP], recombinant, adjuvanted).

Vaccine 52

Vaccine Virus Government Disease 52

The Pharma Data

JUNE 17, 2022

In a Phase 2/3 clinical trial, the Pfizer-BioNTech COVID-19 Vaccine elicited a strong immune response in this age group Three 3-µg doses had favorable safety profile similar to placebo in young children ages 6 months through 4 years in Phase 2/3 clinical trial Pfizer-BioNTech COVID-19 Vaccine now authorized in the U.S. Ugur Sahin, M.D.,

Vaccine 52

Vaccine FDA Clinical Trials Immune Response 52

The Pharma Data

DECEMBER 4, 2021

The first peer-reviewed study in North America examining the timing between the first and second doses of COVID-19 mRNA vaccines shows that a longer dose interval leads to a stronger immune response. The study is funded by the Government of Canada through its COVID-19 Immunity Task Force (CITF).

Immune Response 52

Immune Response Vaccine Hospitals Laboratories 52

The Pharma Data

JUNE 1, 2022

has been appointed Senior Vice President and Head of the Company’s Vaccine Research & Development (R&D) organization effective August 1, succeeding Kathrin U. Annaliesa is a world-class scientist with a track record of delivering both vaccines and therapeutics in pioneering new areas of science and where there is urgent unmet need.

Vaccine 40

Vaccine Research Doctors Laboratories 40

The Pharma Data

DECEMBER 19, 2020

Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that the U.S. 11 ACIP members voted in favor of the vaccine and 0 members voted against. We look forward to vaccinations of this important population starting this week.”. government by the end of December 2020.

Vaccine 52

Vaccine Long-Term Care Facilities FDA Licensing 52

The Pharma Data

MAY 31, 2022

Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Takeda ( TSE:4502/NYSE:TAK ) announced to transfer the marketing authorization in Japan for Moderna’s COVID-19 vaccine Spikevax TM (mRNA-1273) from Takeda to Moderna in Japan as of August 1, 2022. Moderna, Inc., ” Authorized Use.

Vaccine 52

Vaccine Marketing RNA Science 52

The Pharma Data

APRIL 18, 2022

Takeda today announced that it has received manufacturing and marketing approval from the Japan Ministry of Health, Labour and Welfare (MHLW) for Nuvaxovid ® Intramuscular Injection (Nuvaxovid), a novel recombinant protein-based COVID-19 vaccine, for primary and booster immunization in individuals aged 18 and older.

Vaccine 52

Vaccine Clinical Trials Virus Government 52

The Pharma Data

OCTOBER 6, 2021

Pfizer and BioNTech today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion on the administration of the companies’ COVID-19 vaccine as a booster dose at least six months after the second dose in individuals 18?years years of age and older.

Vaccine 52

Vaccine Small Molecule Government Therapies 52

The Pharma Data

OCTOBER 20, 2020

No COVID-19 Vaccines Allowed in California Without State Approval. 20, 2020 — California is not going to allow the use of any COVID-19 vaccines until its own panel of experts approves them, Gov. The governor named 11 doctors and scientists who will review any vaccines approved by the federal government or vaccine developers.

Vaccine 52

Vaccine Doctors Government Production 52

The Pharma Data

DECEMBER 12, 2020

Food and Drug Administration approved Pfizer’s coronavirus vaccine for emergency use on Friday, clearing the way for the launch of a national campaign to inoculate enough Americans to stem the spread of COVID-19. ” Who is first in line to be vaccinated? Centers for Disease Control and Prevention advisory panel.

FDA Approval 52

FDA Approval Vaccine FDA Nurses 52

The Pharma Data

JANUARY 22, 2021

As research developments into RNA vaccines help scientists accelerate drug candidates to arm the immune system against coronavirus, Pharma IQ ’s Keeping tabs on Covid-19 update returns with news from some of the biotechnology innovators leading the fight against the global pandemic.

Vaccine 52

Vaccine Immune Response Government RNA 52

The Pharma Data

AUGUST 27, 2020

Obesity can increase the risk of death from coronavirus by nearly 50% and could make a vaccine less effective, according to a new study. . A coronavirus vaccine may also not work as well in obese recipients. The research was conducted by the University of North Carolina (UNC), the Saudi Health Council and the World Bank.

Vaccine 52

Vaccine Government Virus Hospitals 52

The Pharma Data

MAY 5, 2022

The Fact Sheet for Healthcare Providers Administering Vaccine now reflects the revision of the authorized use of the Janssen COVID-19 Vaccine and includes a warning statement at the beginning of the fact sheet for prominence which summarizes information on the risk for TTS.

Vaccine 52

Vaccine FDA Pharmaceutical Companies Production 52

The Pharma Data

JANUARY 12, 2021

Department of Health and Human Services (HHS) and the Department of Defense (DOD) will purchase additional supply of the casirivimab and imdevimab antibody cocktail for use in non-hospitalized COVID-19 patients to meet the federal government’s Operation Warp Speed goals. Have chronic kidney disease. cardiovascular disease, OR.

Government 52

Government Hospitals Virus Production 52

The Pharma Data

JULY 18, 2021

Food and Drug Administration (FDA) granted Priority Review designation for the Biologics License Application (BLA) for their mRNA vaccine to prevent COVID-19 in individuals 16 years of age and older. The Pfizer-BioNTech COVID-19 vaccine, which is based on BioNTech proprietary mRNA technology, was developed by both BioNTech and Pfizer.

Licensing 52

Licensing Licensing Vaccine FDA 52

The Pharma Data

MARCH 2, 2021

Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, to prevent COVID-19 in individuals 18 years of age and older. The terms of the EUA allow use of the vaccine while more data are gathered.

Vaccine 52

Vaccine Clinical Trials FDA Hospitals 52

The Pharma Data

DECEMBER 14, 2020

14, 2020 (Healthday News) — The first shipments of nearly 3 million doses of the Pfizer coronavirus vaccine were on their way to hospitals in all 50 U.S. Because the vaccines can cause side effects including fevers and aches, hospitals have said they will stagger vaccinations among their workers. MONDAY, Dec.

Vaccine 52

Vaccine Nurses Assisted Living Hospitals 52

The Pharma Data

DECEMBER 8, 2020

The COVID-19 vaccine under development by China’s Sinopharm is showing efficacy of 86%, health authorities from the United Arab Emirates reported this morning. In August, the company reported the vaccine candidate triggered antibody-based immune responses in early and mid-stage trials. Source link.

Vaccine 52

Vaccine Immune Response Virus Clinical Trials 52